Slimming down competition over weight-loss drugs

By Phillip Broadwith2026-02-13T10:36:00

A box of wegovy (semiglutide) injections and a tub of wegovy tablets.

Source: © Michael Siluk/UCG/Universal Images Group/Getty Images

Legal battle between Novo Nordisk and US compounding pharmacy Hims & Hers has fizzled after regulator intervention

Novo won US approval for a tablet version of Wegovy (semaglutide) and began marketing it in January, at a significantly lower price than the injectable form of the drug. In early February, Hims & Hers said it would offer a discounted version of the pill – Novo immediately threatened legal action, claiming patent infringement.